NPT 088

Drug Profile

NPT 088

Alternative Names: NPT-088

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroPhage Pharmaceuticals Inc
  • Developer Proclara Biosciences
  • Class Antiparkinsonians; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Nootropics; Recombinant fusion proteins
  • Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Protein aggregation inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 02 Aug 2018 Phase-I clinical trials in Parkinson's disease in USA (IV) (Proclara Biosciences Pipeline)
  • 17 Jul 2017 Data Monitoring Committee recommends continuation of phase Ib trial
  • 16 Nov 2016 Proclara Biosciences has patent protection for General Amyloid Interaction Motif (GAIM) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top